Last reviewed · How we verify

XS005 Sorafenib Capsule A - Period 2

Xspray Pharma AB · Phase 1 active Small molecule

XS005 Sorafenib Capsule A - Period 2 is a Small molecule drug developed by Xspray Pharma AB. It is currently in Phase 1 development. Also known as: Regimen B, Regimen C.

At a glance

Generic nameXS005 Sorafenib Capsule A - Period 2
Also known asRegimen B, Regimen C
SponsorXspray Pharma AB
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about XS005 Sorafenib Capsule A - Period 2

What is XS005 Sorafenib Capsule A - Period 2?

XS005 Sorafenib Capsule A - Period 2 is a Small molecule drug developed by Xspray Pharma AB.

Who makes XS005 Sorafenib Capsule A - Period 2?

XS005 Sorafenib Capsule A - Period 2 is developed by Xspray Pharma AB (see full Xspray Pharma AB pipeline at /company/xspray-pharma-ab).

Is XS005 Sorafenib Capsule A - Period 2 also known as anything else?

XS005 Sorafenib Capsule A - Period 2 is also known as Regimen B, Regimen C.

What development phase is XS005 Sorafenib Capsule A - Period 2 in?

XS005 Sorafenib Capsule A - Period 2 is in Phase 1.

Related